These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 14696560)

  • 1. Abandon Trizivir when it's working well? A rebuttal.
    Erbelding EJ
    Hopkins HIV Rep; 2003 Jul; 15(4):1. PubMed ID: 14696560
    [No Abstract]   [Full Text] [Related]  

  • 2. AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial.
    Gallant JE
    Hopkins HIV Rep; 2003 Jul; 15(4):1-2. PubMed ID: 14696559
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-HIV agents. Abacavir--as good as AZT?
    TreatmentUpdate; 2003 Oct; 15(6):3-4. PubMed ID: 17216861
    [No Abstract]   [Full Text] [Related]  

  • 4. Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis.
    Moyle GJ; Gazzard BG
    AIDS; 2002 May; 16(7):1086-7. PubMed ID: 11953482
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA notifications. Tentative approval given for combination of abacavir, lamivudine & zidovudine tablets.
    AIDS Alert; 2009 Sep; 24(9):106. PubMed ID: 19928326
    [No Abstract]   [Full Text] [Related]  

  • 6. Report from the XVI International AIDS Conference. Efavirenz for high viral load and low CD4--a secondary analysis of ACTG 5095.
    Feinberg J
    AIDS Clin Care; 2006 Nov; 18(11):99. PubMed ID: 17183745
    [No Abstract]   [Full Text] [Related]  

  • 7. We want our Trizivir!
    Vázquez E
    Posit Aware; 2003; 14(5):25-6. PubMed ID: 14679938
    [No Abstract]   [Full Text] [Related]  

  • 8. [First HIV triple therapy with one tablet].
    Dtsch Med Wochenschr; 2000 Feb; 125(8):A22. PubMed ID: 10723466
    [No Abstract]   [Full Text] [Related]  

  • 9. Triple nuke therapy--results after one year.
    TreatmentUpdate; 2001; 12(10):3-4. PubMed ID: 11570063
    [No Abstract]   [Full Text] [Related]  

  • 10. [Efficacy and safety of the substitution of zidovudine by nevirapine in treatments based on three nucleoside analogue reverse transcriptase inhibitors in HIV-1 infected patients].
    Tasias M; Ruiz S; Deig E; Pedrol E
    Enferm Infecc Microbiol Clin; 2011; 29(7):556-7. PubMed ID: 21565428
    [No Abstract]   [Full Text] [Related]  

  • 11. New formulations approved for children.
    AIDS Patient Care STDS; 2008 Jan; 22(1):88. PubMed ID: 18453043
    [No Abstract]   [Full Text] [Related]  

  • 12. Abacavir plus lamivudine: a thymidine analogue-sparing NRTI backbone.
    Moyle GJ
    AIDS Read; 2003 Nov; 13(11):528, 533-5. PubMed ID: 14649622
    [No Abstract]   [Full Text] [Related]  

  • 13. Abacavir arm stopped in clinical trial.
    James JS
    AIDS Treat News; 2003 Apr; (390):6-7. PubMed ID: 12739475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-HIV agents. Low rate of early virologic failure seen with a combination of Trizivir and tenofovir.
    TreatmentUpdate; 2004 Mar; 16(2):2-3. PubMed ID: 17219666
    [No Abstract]   [Full Text] [Related]  

  • 15. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
    Henry K; Wallace RJ; Bellman PC; Norris D; Fisher RL; Ross LL; Liao Q; Shaefer MS;
    J Infect Dis; 2001 Feb; 183(4):571-8. PubMed ID: 11170982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anatomy of a study: Trizivir vs. Sustiva.
    Berger DS
    Posit Aware; 2003; 14(3):40-1. PubMed ID: 12866492
    [No Abstract]   [Full Text] [Related]  

  • 17. Where now for Trizivir? Role of the triple-NRTI pill post-ACTG 5095.
    Moyle GJ
    AIDS Read; 2003 May; 13(5):223-4, 227, 244. PubMed ID: 12800825
    [No Abstract]   [Full Text] [Related]  

  • 18. Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results.
    Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Van Kasteren ME; Bravenboer B; Ten Kate RW; Groeneveld PH; van der Werf TS; Gisolf EH; Richter C
    AIDS Patient Care STDS; 2010 Jun; 24(6):361-6. PubMed ID: 20515418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral rounds. A very discordant response.
    Henry K; Jenny-Avital E
    AIDS Clin Care; 2002 Jan; 14(1):4-5, 8. PubMed ID: 11802628
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA notifications. Tentative approval for fixed-dose combo abacavir/lamivudine.
    AIDS Alert; 2009 Feb; 24(2):22. PubMed ID: 19219952
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.